Radiopharmaceutical company Telix Pharmaceuticals Ltd. is continuing its buying spree to shore up dominance in the radiopharmaceutical market with its latest acquisition of RLS Radiopharmacies for $250 million to expand its U.S. manufacturing presence and establish a next-generation radiometal production network.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Antengene, Astrazeneca, Elevation, Innate, Ipsen, Lantern, Leo, Merck & Co., Neuraxpharm, Sanofi, UCB, Uniqure.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Bioatla, Context, Crown, Glaukos, Nicox, Revance.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Assembly, Astrazeneca, Biocity, Biohaven, Black Diamond, Ideaya, Immusoft, Oryzon, Realta, Repare, Skye, Teva.
When the U.S. FTC filed suit Sept. 20 against the country’s three largest pharmacy benefit managers over their alleged use of rebates to artificially inflate U.S. insulin prices, it also put the three big insulin makers, and other drug manufacturers, on notice that they could be next.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Amplia, Apellis, Biocon, Biotech, Ipsen, Janssen, Johnson & Johnson, Merck, Novo Nordisk, Pfizer, Samsung Bioepis, Sanofi.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Acadia, Axcelead, Biosyent, Centenara, Mithra, Novalon, Rejuveron.
RSS
